Should All Patients with Resistant Hypertension Receive Spironolactone?

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10329598" target="_blank" >RIV/00064165:_____/16:10329598 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/16:10329598 RIV/00216208:11120/16:43912297
Result on the web
<a href="http://dx.doi.org/10.1007/s11906-016-0690-1" target="_blank" >http://dx.doi.org/10.1007/s11906-016-0690-1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s11906-016-0690-1" target="_blank" >10.1007/s11906-016-0690-1</a>

Result language
angličtina
Original language name
Should All Patients with Resistant Hypertension Receive Spironolactone?
Original language description
Purpose of review: Resistant hypertension is a common clinical situation. Identification of true resistant hypertension (using 24-h ambulatory blood pressure monitoring to exclude white coat phenomenon, excluding secondary causes and non-adherence to treatment) is important mostly because of the application of a proper therapeutic approach and the higher cardiovascular risk of these patients. This review surveys recent studies, with a focus on mineralocorticoid receptor antagonists, including spironolactone, in the treatment of resistant hypertension. Recent findings: A range of randomized and non-randomized studies have proved the efficacy of mineralocorticoid receptor antagonists, including spironolactone. However, long-term mortality studies are still missing for the hypertensive population. In the case of spironolactone side effects, higher doses of amiloride or eplerenone might be used. Summary: Based on available data and our own experience, spironolactone (mineralocorticoid receptor antagonists) should be involved, if tolerated, in combination therapy in true resistant hypertensive patients. Spironolactone still represents primary therapeutic modality under specific conditions of primary aldosteronism.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Project
<a href="/en/project/NV16-30345A" target="_blank" >NV16-30345A: Pheochromocytoma as a model of chronic activation of the stress axis in the pathogenesis of metabolic disorders</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)